Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
Guido Antonelli, Daniele Focosi, Ombretta Turriziani, Marco Tuccori, Rossella Brandi, Silvia Fillo, Camilla Ajassa, Florigio Lista, Claudio Maria Mastroianni
Topics & Concepts
DiscontinuationRitonavirMedicineCoronavirus disease 2019 (COVID-19)Randomized controlled trialMarketing authorizationClinical trialInternal medicineIntensive care medicineDiseaseFamily medicineInfectious disease (medical specialty)Viral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyBioinformaticsBiologySARS-CoV-2 and COVID-19 ResearchAntibiotics Pharmacokinetics and EfficacyHepatitis C virus research